Tempus AI, Inc. (NASDAQ: TEM) is a healthcare technology company that applies artificial intelligence and multimodal data to precision medicine, with a strong focus on oncology and health information services. The Tempus news stream highlights how the company’s platform, genomic testing capabilities, and data-driven tools are used in collaborations, research, and commercial partnerships.
Readers can follow announcements about Tempus’s strategic collaborations with leading health systems and academic medical centers, such as multi-year precision oncology initiatives and efforts to expand access to genomic testing for cancer patients. News items also cover research partnerships with nonprofit foundations, including multi-omic studies designed to build comprehensive datasets for specific diseases like follicular lymphoma.
Tempus frequently reports on its participation in major scientific conferences, where it presents abstracts based on its de-identified multimodal database and tools like Tempus Lens. These updates include studies on tumor genomics, immune microenvironments, biomarkers, and real-world outcomes across a range of cancers, including gastrointestinal, breast, and other solid tumors. In addition, the news feed features corporate and financial updates, such as preliminary revenue results, contract value milestones, and appearances at investor conferences.
By reviewing the latest TEM news, investors and healthcare professionals can see how Tempus’s AI-enabled precision medicine solutions are being applied in clinical settings, research collaborations, and life sciences partnerships. This page is a resource for tracking ongoing developments in Tempus’s diagnostics, data and applications businesses, as well as its role in advancing data-driven approaches to cancer care and therapeutic development.
Ares Management (NYSE: ARES) has expanded its debt financing for Tempus AI (NASDAQ: TEM) with an additional $300 million, bringing the total debt package to $560 million. The new financing supports Tempus' recent acquisition of Ambry Genetics, which closed on February 3, 2025.
Tempus, founded in 2015, specializes in implementing AI solutions in healthcare, focusing on clinical care and research products. The company's integrated business model includes patient sequencing, data collection through licensing and analytical tools, and diagnostic testing insights across oncology, cardiology, pathology, and radiology.
This financing demonstrates Ares' capability to provide scalable capital to both non-sponsor-backed and sponsor-backed borrowers, with Ares expressing confidence in Tempus' growth strategy and the strategic acquisition of Ambry.
Tempus AI (NASDAQ: TEM) has announced its participation in the upcoming Morgan Stanley Technology, Media & Telecom Conference scheduled for March 3-6, 2025, in San Francisco, CA. The company's Founder and CEO, Eric Lefkofsky, will engage in a fireside discussion on March 3, 2025. The event will be accessible to viewers through a live webcast.
Tempus, which specializes in leveraging AI technology for precision medicine and patient care advancement, will use this platform to share insights about their operations and innovations. This participation represents an important opportunity for investors and stakeholders to gain direct insights into the company's strategies and developments.
Tempus AI (NASDAQ: TEM) announced a collaboration with the Institute for Follicular Lymphoma Innovation (IFLI) to develop a real-world multimodal, deidentified follicular lymphoma (FL) data library within Tempus' Lens platform. The initiative aims to accelerate the development of targeted therapies for FL patients through AI-driven insights.
The collaboration will initially focus on generating multimodal FL data for POD24 patients - those experiencing disease progression within 24 months of treatment - through a Tempus-sponsored study. The data library is expected to enhance researchers' understanding of FL biology and support the development of precision medicines by providing insights into the disease's heterogeneity.
The partnership combines IFLI's specialized FL focus with Tempus' AI-enabled solutions to create a centralized database that will be accessible to researchers and professionals working to combat follicular lymphoma.
Tempus AI (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, has scheduled its fourth quarter and full year 2024 financial results announcement for Monday, February 24, 2025. The earnings conference call will be held at 4:30 p.m. ET on the same day.
The call will feature presentations from CEO Eric Lefkofsky and CFO Jim Rogers. Investors can access the live audio webcast through Tempus' Investor Relations website's events page or join via phone using the provided domestic (888-596-4144) and international (646-968-2525) dial-in numbers with Conference ID: 9601821.
Tempus AI (NASDAQ: TEM) has completed its acquisition of Ambry Genetics, a genetic testing company focused on understanding genetics-disease relationships. The transaction, valued at $600 million total, consists of $375 million in cash and $225 million in shares, with $100 million subject to a one-year lock-up period. The acquisition was financed by Ares Management Credit funds.
Tempus CEO Eric Lefkofsky emphasized that this strategic acquisition enhances their capability to deliver advanced solutions to clinicians, patients, and life sciences companies by combining diagnostics and data. Ambry Genetics will continue operating as a wholly-owned subsidiary of Tempus, maintaining its current leadership team.
Genialis has extended its collaboration with Debiopharm to develop predictive biomarkers for WEE1-targeted therapy in cancer treatment. The partnership, building on a 2024 agreement, focuses on discovering biomarkers within the DNA damage response (DDR) biological space. Debiopharm's WEE1 asset is currently in Phase 1 clinical research.
The collaboration leverages the Genialis™ Supermodel, an AI-powered foundation model that enables rapid biomarker configuration across cancer drug targets. This technology, trained on hundreds of thousands of RNA-seq samples, helps stratify response groups and identify mechanisms of response and resistance.
The announcement follows Genialis' recent multi-year agreement with Tempus AI (NASDAQ: TEM) to validate RNA-based biomarker algorithms using Tempus' multimodal dataset. Genialis will present their findings at the 8th Annual DDR Inhibitors Summit and AACR Annual Meeting in 2025.
Tempus (NASDAQ: TEM) has announced the national launch of olivia, an AI-enabled personal health concierge app designed to centralize patient health data and make it actionable. The app connects to over 1,000 health systems through EHR integration and allows users to sync health device data or manually upload records.
Key features include: AI-generated smart profile summaries detailing clinical diagnoses and medications; AI-enabled notetaker for physician appointments; DICOM image sharing through a browser-native platform called pixel; health monitoring capabilities with Apple Health and Google Fit integration; and direct data import from healthcare providers.
The app organizes health information into a dynamic timeline, allowing patients to access records, lab results, and imaging reports. Users can query their health data using natural language, receiving AI-powered responses and insights. olivia is now available on both iOS and Android platforms.
Tempus AI (NASDAQ: TEM) has announced the nationwide launch of its FDA-approved xT CDx test, a comprehensive 648-gene next-generation sequencing test for solid tumor profiling. The test includes microsatellite instability status and companion diagnostic claims for colorectal cancer patients.
The xT CDx employs a normal-matched approach, conducting parallel DNA sequencing of solid tumor and normal patient samples for more accurate identification of cancer-driving somatic variants. All existing tumor + normal match tests previously run on Tempus's signature xT assay will now be processed as xT CDx, maintaining the current ordering workflow.
Clinicians can enhance molecular insights by combining xT CDx with additional tests including xR RNA sequencing, xF/xF+ liquid biopsy, immunohistochemistry tests, and algorithmic tests for homologous recombination deficiency and immune profile scoring.
Tempus AI (NASDAQ: TEM) has unveiled new generative AI capabilities for its Tempus One platform, enhancing its ability to analyze unstructured healthcare data. The platform now features four key innovations: Patient Query for improved clinical trial matching, Patient Timeline for comprehensive patient journey visualization, Prior Authorization to streamline administrative processes, and Data Exploration for advanced research capabilities.
These new features leverage Tempus' proprietary Large Language Model (LLM) Agent Infrastructure to process millions of unstructured documents, including progress notes, pathology reports, and imaging scans. The system can now create structured timelines of clinical events, facilitate patient enrollment in clinical trials, assist with prior authorization documentation, and enable researchers to analyze de-identified datasets more efficiently.
Tempus AI (NASDAQ: TEM) announced the development of xH, its first whole-genome sequencing (WGS) test, focusing on hematological oncology. The test, currently available for research use only, will be clinically available within the next year. xH is designed to support both clinicians and biopharma collaborators by providing comprehensive genetic profiling.
In a pilot study of 135 patients, the WGS assay demonstrated high accuracy with a concordance rate exceeding 98.9% compared to traditional molecular methods. The test showed particular effectiveness in detecting guideline-recommended structural variants and large copy number alterations in myeloid malignancies, including Acute Myeloid Leukemia, Myelodysplastic Syndromes, and Myeloproliferative neoplasms. This comprehensive approach aims to consolidate multiple tests into a single assay, potentially offering a more cost-effective solution for genomic profiling.